Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: The HOST-ASSURE randomized trial (Harmonizing Optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen)

JACC: Cardiovascular Interventions

Volumn 6, Issue 9, 2013, Pages 932-942

  Kim, Hyo Soo ^a   Park, Kyung Woo ^a   Kang, Si Hyuck ^a   Park, Jin Joo ^a   Yang, Han Mo ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Park, Byoung Eun ^b   Cha, Kwang Soo ^c   Rhew, Jay Young ^d   Jeon, Hui Kyoung ^e   Shin, Eun Seok ^f   Oh, Ju Hyeon ^g   Jeong, Myung Ho ^h   Kim, Sanghyun ⁱ   Hwang, Kyung Kuk ^j   Yoon, Jung Han ^k   Lee, Sung Yun ^l   Park, Tae Ho ^m   Moon, Keon Woong ⁿ   Kwon, Hyuck Moon ^o   Chae, In Ho ^p   more..

^a Seoul National University Hospital   (South Korea)

^b Dankook University   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d Presbyterian Medical Center   (South Korea)

^e Uijeongbu St Mary's Hospital   (South Korea)

^f Ulsan University College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Chonnam National University Medical School   (South Korea)

ⁱ Seoul National University Boramae Hospital   (South Korea)

^j Chungbuk National University Hospital   (South Korea)

^k Wonju Severance Christian Hospital   (South Korea)

^l Inje University   (South Korea)

^m Dong A Medical Center   (South Korea)

ⁿ The Catholic University of Korea   (South Korea)

^o Yonsei University College of Medicine   (South Korea)

^p Seoul National University Bundang Hospital   (South Korea)

more..

Author keywords

antiplatelet therapy; cliostazol; clopidogrel; randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONFATAL MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PRIORITY JOURNAL; SILENT MYOCARDIAL ISCHEMIA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACS; ACUTE CORONARY SYNDROMES; ANTIPLATELET THERAPY; CI; CLIOSTAZOL; CLOPIDOGREL; CONFIDENCE INTERVAL; DDAT; DOUBLE-DOSE CLOPIDOGREL DUAL ANTIPLATELET THERAPY; HIGH ON-TREATMENT PLATELET REACTIVITY; HOPR; MI; MYOCARDIAL INFARCTION; ON-TREATMENT PLATELET REACTIVITY; OPR; PCI; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; TAT; TRIPLE ANTIPLATELET THERAPY;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REPUBLIC OF KOREA; RISK FACTORS; STROKE; TETRAZOLES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884398491     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.04.022     Document Type: Article

References (38)

1. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
2. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
3. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
4. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
5. K.W. Park, K.H. Jeon, and S.H. Kang Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study) Am J Cardiol 108 2011 1556 1563
6. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
7. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
8. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
9. K.W. Park, J.J. Park, and S.P. Lee Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial Heart 97 2011 641 647
10. K.Y. Chen, S.W. Rha, and Y.J. Li Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation 119 2009 3207 3214
11. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
12. J.S. Woo, W. Kim, and S.R. Lee Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study Am Heart J 162 2011 1018 1025
13. K.W. Park, B.-E. Park, and S.-H. Kang The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial Trials 13 2012 29
14. S. James, A. Akerblom, and C.P. Cannon Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 157 2009 599 605
15. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
16. S.S. Brar, J. ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
17. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
18. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
19. D. Hazarbasanov, V. Velchev, and B. Finkov Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention J Thromb Thrombolysis 34 2012 85 90
20. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity Int J Cardiol 160 2012 109 113
21. H. Ari, H. Ozkan, A. Karacinar, S. Ari, V. Koca, and T. Bozat The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial) Int J Cardiol 157 2012 374 380
22. T. Cuisset, J. Quilici, and W. Cohen Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome Am J Cardiol 108 2011 760 765
23. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716
24. G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, and G. Di Sciascio High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study J Am Coll Cardiol 57 2011 771 778
25. S.J. Hwang, Y.H. Jeong, and I.S. Kim The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention Thromb Res 127 2011 23 28
26. I.Y. Oh, K.W. Park, and S.H. Kang Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents Heart 98 2012 139 144
27. K.W. Park, J.J. Park, and K.H. Jeon Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans Cardiovasc Ther 30 2012 5 11
28. S.W. Lee, S.W. Park, and Y.H. Kim Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients) J Am Coll Cardiol 51 2008 1181 1187
29. S.W. Lee, S.W. Park, and Y.H. Kim A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial J Am Coll Cardiol 57 2011 1264 1270
30. J.W. Suh, S.P. Lee, and K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 2011 280 289
31. J.L. Ferreiro, M. Ueno, B. Desai, P. Capranzano, D. Capodanno, and D.J. Angiolillo Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus Rev Esp Cardiol 65 2012 105 106
32. Y.H. Jeong, J.Y. Hwang, and I.S. Kim Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study Circ Cardiovasc Interv 3 2010 17 26
33. I.S. Kim, Y.H. Jeong, and Y. Park Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype J Am Coll Cardiol Intv 4 2011 381 391
34. D.S. Sim, G. Merrill-Skoloff, B.C. Furie, B. Furie, and R. Flaumenhaft Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels Blood 103 2004 2127 2134
35. S. Nomura, N. Inami, T. Iwasaka, and Y. Liu Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole Platelets 15 2004 167 172
36. D.J. Angiolillo, P. Capranzano, and J.L. Ferreiro Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy Thromb Haemost 106 2011 253 262
37. D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
38. K.W. Park, I.H. Chae, and D.S. Lim Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial J Am Coll Cardiol 58 2011 1844 1854